← Leaderboards
John Tanner Wilson
Vanderbilt University
$7,006,172
Attributed
$7,943,883
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,943,883 · 5
By mechanism
R01$7,525,863 · 4
R21$418,020 · 1
Top collaborators
- Anna Marie Pyle4 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Ann Richmond$15,857,391
- Jessalyn J Baljon$119,772
- Kennady Bullock$40,447
- Chi Yan$353,319
- Julie A Sterling$3,669,071
Others in their field
Top investigators on “Multidisciplinary”
- Lawrence Corey · Fred Hutchinson Cancer Center$298,997,339
- David Heimbrook · Leidos Biomedical Research, Inc.$251,484,793
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Gregory H Reaman · National Childhood Cancer Foundation$201,951,987
- Judith S. Currier · University Of California Los Angeles$188,628,043
- Barton F Haynes · Duke University$186,871,361
Research focus
MultidisciplinaryImmunogenicityAgonistNanoparticleDrug Delivery SystemsDesignResponseTumor MicroenvironmentSciencePharmacologic SubstanceTumorPropertyTumor ImmunityNatural ImmunityPolymersEndosomesEngineeringUptakeInvestigationPathway InteractionsCytosolDrug KineticsBiodistributionDinucleoside Phosphates
Grant awards (20)
RIG-I Activating Nanoparticles for Immunopotentiation$597,471
R01 · FY2025 · EB · contact PI
Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma$564,686
R01 · FY2025 · CA · contact PI
Engineered Vaccines for Neoantigen Targeted Cancer Immunotherapy$491,618
R01 · FY2025 · CA · contact PI
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy$225,703
R01 · FY2025 · CA · contact PI
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy$346,493
R01 · FY2024 · CA · contact PI
Engineered Vaccines for Neoantigen Targeted Cancer Immunotherapy$221,278
R01 · FY2024 · CA · contact PI
Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma$150,851
R01 · FY2024 · CA · contact PI
RIG-I Activating Nanoparticles for Immunopotentiation$78,223
R01 · FY2024 · EB · contact PI
Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma$632,304
R01 · FY2023 · CA · contact PI
RIG-I Activating Nanoparticles for Immunopotentiation$594,047
R01 · FY2023 · EB · contact PI
Engineered Vaccines for Neoantigen Targeted Cancer Immunotherapy$553,633
R01 · FY2023 · CA · contact PI
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy$357,393
R01 · FY2023 · CA · contact PI
Engineered Vaccines for Neoantigen Targeted Cancer Immunotherapy$638,247
R01 · FY2022 · CA · contact PI
RIG-I Activating Nanoparticles for Immunopotentiation$605,681
R01 · FY2022 · EB · contact PI
Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma$604,335
R01 · FY2022 · CA · contact PI
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy$364,644
R01 · FY2022 · CA · contact PI
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy$135,806
R01 · FY2021 · CA · contact PI
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy$363,450
R01 · FY2020 · CA · contact PI
Engineered Nanoparticles for Protective Subunit Vaccine Delivery and Discovery$189,284
R21 · FY2017 · AI · contact PI
Engineered Nanoparticles for Protective Subunit Vaccine Delivery and Discovery$228,736
R21 · FY2016 · AI · contact PI